Jose Ignacio Varillas

Jose Ignacio Varillas

Auto-generated profile, based on publicly available information

Jose Ignacio Varillas

J. Crayton Pruitt Family Department of Biomedical Engineering University of Florida Gainesville FL 32611 USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2019 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
Kangfu ChenKangfu Chen
Kangfu Chen
PDPablo Dopico
Pablo Dopico
JVJose Varillas
Jose Varillas
JZJinling Zhang
Jinling Zhang
TGThomas J George
Thomas J George
Z. Hugh FanZ. Hugh Fan
Z. Hugh Fan

1 January 2019 in Theranostics
Verified
Journal Article
Open access
JVJose I. Varillas
Jose I. Varillas
JZJinling Zhang
Jinling Zhang
Kangfu ChenKangfu Chen
Kangfu Chen
IBIsis I. Barnes
Isis I. Barnes
CLChen Liu
Chen Liu
Z. Hugh FanZ. Hugh Fan
Z. Hugh Fan
Background: Pancreatic ductal adenocarcinoma (PDAC) requires multimodal therapeutic approaches and disease monitoring for effective treatment. Liquid biopsy biomarkers, including circulating tumor cells (CTCs) and cancer stem-like cells (CSCs), hold promise for evaluating treatment response promptly and guiding therapeutic modifications.

1 September 2017 in Biomicrofluidics
Verified
Journal Article
Closed access
Kangfu ChenKangfu Chen
Kangfu Chen
TGTeodor Z. Georgiev
Teodor Z. Georgiev
WSWeian Sheng
Weian Sheng
XZXiangjun Zheng
Xiangjun Zheng
JVJose I. Varillas
Jose I. Varillas
Z. Hugh FanZ. Hugh Fan
Z. Hugh Fan
Circulating tumor cells (CTCs) have shown potential for cancer diagnosis and prognosis. Affinity-based CTC isolation methods have been proved to be efficient for CTC detection in clinical blood samples. One of the popular choices for affinity-based CTC isolation is to immobilize capture agents onto an array of microposts in microchannels, providing high CTC capture efficiency due to enhanced interactions between tumor cells and capture agents on the microposts. However, how the cells interact with microposts under different flow conditions and what kind of capture pattern results from the interactions have not been fully investigated; a full understanding of these interactions will help to design devices and choose experimental conditions for higher CTC capture effeciency. We report our study on their interaction and cell distribution patterns around microposts under different flow conditions. Human acute lymphoblastic leukemia cells (CCRF-CEM) were used as target cancer cells in this study, while the Sgc8 aptamer that has specific binding with CCRF-CEM cells was employed as a capture agent. We investigated the effects of flow rates and micropost shapes on the cell capture efficiency and capture patterns on microposts. While a higher flow rate decreased cell capture efficiency, we found that the capture pattern around microposts also changed, with much more cells captured in the front half of a micropost than at the back half. We also found the ratio of cells captured on microposts to the cells captured by both microposts and channel walls increased as a function of the flow rate. We compared circular microposts with an elliptical shape and found that the geometry affected the capture distribution around microposts. In addition, we have developed a theoretical model to simulate the interactions between tumor cells and micropost surfaces, and the simulation results are in agreement with our experimental observation.

8 April 2019 in Angewandte Chemie
Verified
Journal Article
Closed access
PDF file
Kangfu ChenKangfu Chen
Kangfu Chen
PDPablo Dopico
Pablo Dopico
JVJose I. Varillas
Jose I. Varillas
JZJinling Zhang
Jinling Zhang
TGThomas J George
Thomas J George
Z. Hugh FanZ. Hugh Fan
Z. Hugh Fan

18 August 2017
Verified
Book Chapter
Closed access
PDF file
JVJose I. Varillas
Jose I. Varillas
Kangfu ChenKangfu Chen
Kangfu Chen
JZJinling Zhang
Jinling Zhang
TGThomas J George
Thomas J George
Z. Hugh FanZ. Hugh Fan
Z. Hugh Fan

1 August 2015 in Cancer Research
Verified
Journal Article
Closed access
TGThomas J. George
Thomas J. George
WSWeian Sheng
Weian Sheng
JVJose I. Varillas
Jose I. Varillas
CLChen Liu
Chen Liu
ZFZ. Hugh Fan
Z. Hugh Fan
For most solid tumors, the clinical use of CTCs is limited by current instrument restrictions on detection of infrequent CTCs. Based on the FDA-approved criteria used in current CTC detection instruments, we developed a microfluidic device capable of capturing, enumerating and releasing low numbers of CTCs in the peripheral blood of patients with solid tumors. The device is the size of a microscope slide, consisting of an inlet, an outlet, and eight parallel channels connecting them. Micromixers inside the channels enhance interactions between CTCs and capture agents on the channel surfaces. Epithelial cell-adhesion molecule (EpCAM) antibodies are immobilized onto the surfaces via avidin-biotin chemistry. A blood sample from a cancer patient is introduced through the inlet. Cells captured by anti-EpCAM studded channels are verified as CTCs using triple-color IHC definitions (EpCAM+, cytokeratin+, CD45-, and DAPI+). Using pancreatic cancer as a model for a low frequency CTC condition, device capture efficiency and cell purity was tested under various flow rates (shear stresses) using L3.6pl cells spiked into blood. Capture efficiency was defined as the% of target cells isolated relative to target cells present in a sample, representing device sensitivity. Cell purity was defined as the% of target cells isolated relative to all cells captured (both target and non-target cells), representing device specificity. Capture efficiency (90%) and cell purity (84%) were further optimized by changing the flow rate. A higher flow rate resulted in higher cell purity as non-target bound cells are dislodged by shear forces. This capability of parameter adjustment and performance control is enabled by the microfluidics platform used as opposed to CTC isolation using other commercially approved technologies. The device was then clinically tested in detecting CTCs and monitoring the response to anti-cancer drug treatment in patients with advanced pancreatic cancer. We identified CTCs in 113 out of 115 clinical blood samples (98%). CTC enumeration (CTC number/mL of blood) both correlated with and predated changes in the radiographic tumor size over the treatment period, ranging from 10 to 35 cycles (2 weeks per cycle) of therapy. Microfluidic devices possess the capacity to enumerate infrequent CTCs which also appear to correlate with treatment response. Note: This abstract was not presented at the meeting. Citation Format: Thomas J. George, Weian Sheng, Jose I. Varillas, Chen Liu, Z. Hugh Fan. Identification of low number circulating tumor cells (CTCs) for cancer treatment monitoring. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1607. doi:10.1158/1538-7445.AM2015-1607